During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 1.2 million, with the beta value of the company hitting 1.12. At the end of the trading day, the stock’s price was $11.88, reflecting an intraday loss of -8.05% or -$1.04. The 52-week high for the ESPR share is $39.49, that puts it down -232.41 from that peak though still a striking 7.58% gain since the share price plummeted to a 52-week low of $10.98. The company’s market capitalization is $325.16M, and the average intraday trading volume over the past 10 days was 1.41 million shares, and the average trade volume was 710.31K shares over the past three months.
Esperion Therapeutics Inc. (ESPR) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.50. ESPR has a Sell rating from 2 analyst(s) out of 11 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$2.79.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Esperion Therapeutics Inc. (ESPR) registered a -8.05% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -8.05% in intraday trading to $11.88 this Wednesday, 09/22/21, hitting a weekly high. The stock’s 5-day price performance is 4.76%, and it has moved by -13.98% in 30 days. Based on these gigs, the overall price performance for the year is -68.24%. The short interest in Esperion Therapeutics Inc. (NASDAQ:ESPR) is 9.02 million shares and it means that shorts have 14.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $41.73, which implies an increase of 71.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $114.00 respectively. As a result, ESPR is trading at a discount of -859.6% off the target high and 32.66% off the low.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Statistics show that Esperion Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Esperion Therapeutics Inc. (ESPR) shares have gone down -55.90% during the last six months, with a year-to-date growth rate less than the industry average at -99.43% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 9.10% this quarter and then jump 34.40% in the quarter after that. In the rating firms’ projections, revenue will decrease -61.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $16.53 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $21.91 million by the end of Dec 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -18.20%. While earnings are projected to return -45.70% in 2021, the next five years will return 16.90% per annum.
Esperion Therapeutics Inc. is due to release its next quarterly earnings between November 01 and November 05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
Esperion Therapeutics Inc. insiders own 1.58% of total outstanding shares while institutional holders control 108.45%, with the float percentage being 110.19%. Wasatch Advisors Inc is the largest shareholder of the company, while 222 institutions own stock in it. As of Mar 30, 2021, the company held over 4.12 million shares (or 14.56% of all shares), a total value of $115.51 million in shares.
The next largest institutional holding, with 3.99 million shares, is of Bellevue Group AG’s that is approximately 14.11% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $111.9 million.
Also, the Mutual Funds coming in first place with the largest holdings of Esperion Therapeutics Inc. (ESPR) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Wasatch Ultra Growth Fund. Data provided on Jun 29, 2021 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 1.72 million shares. This amounts to just over 6.07 percent of the company’s overall shares, with a $36.33 million market value. The same data shows that the other fund manager holds slightly less at 1.32 million, or about 4.67% of the stock, which is worth about $37.05 million.